Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result ... long-acting peptides and oral small molecule agonists we are developing ...

Phase 2 stage CT-388, a dual GLP-1/GIP receptor agonist injected subcutaneously, CT-996, a Phase 1 stage oral, small molecule GLP-1 receptor agonist, and CT-868, a Phase-2, once-daily subcutaneous ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

A doctor emphasized that ozempic, a lab-engineered drug, effectively activates GLP-1 receptors for weight loss, unlike foods ...

“GLP-1 agonists have been transformative for patients struggling ... selective, and gut-specific small molecule inhibitor of intestinal microsomal triglyceride transfer protein (iMTP). The overall ...

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...